Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Sep;99(9):1419-23.
doi: 10.1016/s0161-6420(92)31790-7.

Low-dose methotrexate therapy for ocular inflammatory disease

S S Shah  1 , C Y Lowder, M A Schmitt, W S Wilke, G S Kosmorsky, D M Meisler
Affiliations

Low-dose methotrexate therapy for ocular inflammatory disease

S S Shah et al. Ophthalmology. 1992 Sep.

Abstract

Background: Methotrexate is a second-line anti-inflammatory agent used in the treatment of rheumatic diseases. At low doses (12.5 mg/week), it is associated with few serious side effects.

Methods: Twenty-two patients (5 men, 17 women) with chronic noninfectious ocular inflammatory disease, who had not responded to or who had become intolerant of corticosteroid or alternate cytotoxic agents, were treated weekly with oral low-dose, pulse methotrexate. Treated diseases included chronic uveitis-vitreitis (9), scleritis (4), inflammatory pseudotumor (3), orbital myositis (3), and retinal vasculitis (3).

Results: Follow-up ranged from 2 to 39 months (mean, 11 months). Response time ranged from 3 to 9 weeks (mean, 5 weeks) after implementation of methotrexate therapy. Sixteen of 22 patients had reduction of inflammatory activity. Fourteen of these 16 patients were able to taper or discontinue corticosteroid therapy. Five patients had complete remission of their disease; six patients did not respond to methotrexate.

Conclusion: Treatment with low-dose methotrexate appears to be effective therapy for steroid-resistant ocular inflammatory disease.

PubMed Disclaimer